BRPI0707334B8 - formulação de cápsula de gelatina mole de um composto 15-ceto-prostaglandina e método para estabilização do um composto 15-cetoprostaglandina - Google Patents

formulação de cápsula de gelatina mole de um composto 15-ceto-prostaglandina e método para estabilização do um composto 15-cetoprostaglandina

Info

Publication number
BRPI0707334B8
BRPI0707334B8 BRPI0707334A BRPI0707334A BRPI0707334B8 BR PI0707334 B8 BRPI0707334 B8 BR PI0707334B8 BR PI0707334 A BRPI0707334 A BR PI0707334A BR PI0707334 A BRPI0707334 A BR PI0707334A BR PI0707334 B8 BRPI0707334 B8 BR PI0707334B8
Authority
BR
Brazil
Prior art keywords
compound
keto
gelatin capsule
soft gelatin
prostaglandin
Prior art date
Application number
BRPI0707334A
Other languages
English (en)
Inventor
Hirata Ryu
Ueno Ryuji
Harada Yasuhiro
Hashitera Yukiko
Original Assignee
R Tech Ueno Ltd
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38169220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0707334(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by R Tech Ueno Ltd, Sucampo Ag filed Critical R Tech Ueno Ltd
Publication of BRPI0707334A2 publication Critical patent/BRPI0707334A2/pt
Publication of BRPI0707334A8 publication Critical patent/BRPI0707334A8/pt
Publication of BRPI0707334B1 publication Critical patent/BRPI0707334B1/pt
Publication of BRPI0707334B8 publication Critical patent/BRPI0707334B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

formulação de cápsula de gelatina mole e método para estabilização de um composto 15-ceto-prostaglandina. a presente invenção refere-se a uma formulação de cápsula de gelatina mole de um composto 15-ceto-prostaglandina, a qual compreende: um invólucro de cápsula de gelatina mole e álcool de açúcar como um plastificante, e uma mistura compreendendo um composto 15-ceto-prostaglandina e um veículo farmaceuticamente aceitável enche o invólucro. através da encapsulação do composto 15-ceto-prostaglandina no invólucro de cápsula de gelatina mole especificado, a estabilidade do composto é significantemente aperfeiçoada.
BRPI0707334A 2006-01-24 2007-01-23 formulação de cápsula de gelatina mole de um composto 15-ceto-prostaglandina e método para estabilização do um composto 15-cetoprostaglandina BRPI0707334B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76136006P 2006-01-24 2006-01-24
US60/761,360 2006-01-24
PCT/JP2007/051329 WO2007086536A2 (en) 2006-01-24 2007-01-23 Soft-gelatin capsule formulation

Publications (4)

Publication Number Publication Date
BRPI0707334A2 BRPI0707334A2 (pt) 2011-05-03
BRPI0707334A8 BRPI0707334A8 (pt) 2018-04-10
BRPI0707334B1 BRPI0707334B1 (pt) 2021-02-23
BRPI0707334B8 true BRPI0707334B8 (pt) 2021-05-25

Family

ID=38169220

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0707334A BRPI0707334B8 (pt) 2006-01-24 2007-01-23 formulação de cápsula de gelatina mole de um composto 15-ceto-prostaglandina e método para estabilização do um composto 15-cetoprostaglandina

Country Status (16)

Country Link
US (4) US8026393B2 (pt)
EP (1) EP1978944B1 (pt)
JP (1) JP4783794B2 (pt)
KR (1) KR101393944B1 (pt)
CN (3) CN104971056A (pt)
AU (1) AU2007208632B2 (pt)
BR (1) BRPI0707334B8 (pt)
CA (1) CA2637274C (pt)
DK (1) DK1978944T3 (pt)
ES (1) ES2392590T3 (pt)
IL (1) IL192867A (pt)
MX (1) MX2008009650A (pt)
NZ (1) NZ570191A (pt)
PT (1) PT1978944E (pt)
RU (1) RU2420291C3 (pt)
WO (1) WO2007086536A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1978944T3 (da) * 2006-01-24 2012-11-05 Sucampo Ag Blød-gelatine-kapselformulering
AU2008276840B2 (en) 2007-07-19 2013-10-03 R-Tech Ueno, Ltd. Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound
SI2180882T1 (sl) † 2007-10-19 2013-05-31 Otsuka Pharmaceutical Co., Ltd. Trdni matriksni farmacevtski pripravek
NZ598783A (en) * 2009-09-18 2013-07-26 Adolor Corp Use of opioid receptor antagonist for gastrointestinal tract disorders
WO2011054087A1 (en) 2009-11-03 2011-05-12 Bernard Charles Sherman Stable pharmaceutical formulations comprising lubiprostone
JP2014515004A (ja) * 2011-04-27 2014-06-26 スキャンポ・アーゲー イオン輸送体の調節方法
US9661844B2 (en) * 2012-04-30 2017-05-30 Dow Agrosciences Llc Pesticide composition delivery vehicles
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
EP3273948B1 (en) 2015-03-26 2020-02-12 Patheon Softgels Inc. Liquisoft capsules
JP2018536017A (ja) 2015-09-22 2018-12-06 グレイバグ ビジョン インコーポレイテッド 眼障害の治療のための化合物及び組成物
CN107638403B (zh) * 2016-07-22 2020-05-05 江苏威凯尔医药科技有限公司 一种硬胶囊制剂
US11534404B2 (en) 2016-10-06 2022-12-27 Sucampo Ag Multilayer beads for pharmaceutical use
GB201711157D0 (en) * 2017-07-11 2017-08-23 Univ Liverpool Sulfur-Doped Carbonaceous porous materials
CN108619107A (zh) * 2018-05-28 2018-10-09 青海制药厂有限公司 一种含鲁比前列酮的软胶囊及其制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8305693D0 (en) * 1983-03-02 1983-04-07 Scherer Ltd R P Pharmaceutical compositions
US4755531A (en) * 1986-08-11 1988-07-05 Syntex (U.S.A.) Inc. Thiol esters of 4,5-allenyl prostaglandins and use thereof as antigastric secretion agents
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5428062A (en) 1987-01-28 1995-06-27 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5225439A (en) * 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1324129C (en) 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5591887A (en) 1987-04-30 1997-01-07 R-Tech Ueno, Ltd. Prostaglandins of the F series
EP0292964B1 (en) 1987-05-28 1995-04-05 Hiroshi Maeda Superoxide dismutase derivatives a method of producing the same and medicinal use of the same
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
US5048022A (en) * 1989-08-01 1991-09-10 Digital Equipment Corporation Memory device with transfer of ECC signals on time division multiplexed bidirectional lines
DE69018903T2 (de) 1989-08-09 1995-08-24 Ueno Seiyaku Oyo Kenkyujo Kk Verwendung von Prostansäurederivaten zur Herstellung von Arzneimitteln zur Verbesserung der Ausscheidung von Nichtprotein in die Därme.
US5254588A (en) 1989-11-22 1993-10-19 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds
JPH07100655B2 (ja) * 1990-04-04 1995-11-01 株式会社アールテック・ウエノ 白内障処置剤
TW224942B (pt) 1990-04-04 1994-06-11 Adka Ueno Kk
CA2041417C (en) 1990-05-01 2002-05-21 Ryuji Ueno Treatment of pancreatic disease with 15-keto-prostaglandin compounds
JPH04187637A (ja) * 1990-11-21 1992-07-06 Ueno Seiyaku Oyo Kenkyusho:Kk 記憶改善剤
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
KR19990036322A (ko) 1996-06-10 1999-05-25 류지 우에노 엔도텔린길항제
US5998438A (en) * 1996-11-26 1999-12-07 Allelix Biopharmaceuticals, Inc. 5-cyclo indole compounds
US6207699B1 (en) * 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
DE60010913T2 (de) 1999-10-15 2005-06-09 Sucampo Ag Bizyklische Verbindungen, Zusammenstellung und Verfahren zu ihrer Stabilisierung
KR20030076692A (ko) * 2001-02-22 2003-09-26 오노 야꾸힝 고교 가부시키가이샤 디클로페낙과 오르노프로스틸로 이루어지는 의약 조성물
TWI331920B (en) * 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
DE602004030245D1 (de) * 2003-07-03 2011-01-05 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
CN1257711C (zh) * 2003-12-05 2006-05-31 石药集团中奇制药技术（石家庄）有限公司 丁苯酞软胶囊及其制备工艺
AU2007208637B2 (en) * 2006-01-24 2012-04-26 R-Tech Ueno, Ltd. Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
DK1978944T3 (da) * 2006-01-24 2012-11-05 Sucampo Ag Blød-gelatine-kapselformulering
AU2008276840B2 (en) * 2007-07-19 2013-10-03 R-Tech Ueno, Ltd. Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound

Also Published As

Publication number Publication date
KR20080090526A (ko) 2008-10-08
BRPI0707334A2 (pt) 2011-05-03
CN104983712A (zh) 2015-10-21
IL192867A (en) 2015-06-30
RU2008134489A (ru) 2010-02-27
CA2637274A1 (en) 2007-08-02
MX2008009650A (es) 2008-11-06
JP4783794B2 (ja) 2011-09-28
US20130078303A1 (en) 2013-03-28
WO2007086536A2 (en) 2007-08-02
BRPI0707334A8 (pt) 2018-04-10
NZ570191A (en) 2010-09-30
PT1978944E (pt) 2012-11-26
US20070172523A1 (en) 2007-07-26
EP1978944B1 (en) 2012-08-15
AU2007208632B2 (en) 2012-01-19
AU2007208632A1 (en) 2007-08-02
EP1978944A2 (en) 2008-10-15
JP2008534432A (ja) 2008-08-28
RU2420291C2 (ru) 2011-06-10
ES2392590T3 (es) 2012-12-12
DK1978944T3 (da) 2012-11-05
WO2007086536A3 (en) 2007-11-15
KR101393944B1 (ko) 2014-05-12
CN101410097A (zh) 2009-04-15
IL192867A0 (en) 2009-02-11
RU2420291C3 (ru) 2020-07-21
BRPI0707334B1 (pt) 2021-02-23
US8026393B2 (en) 2011-09-27
US20110300211A1 (en) 2011-12-08
US8779187B2 (en) 2014-07-15
US8338639B2 (en) 2012-12-25
CA2637274C (en) 2013-06-04
US20140287036A1 (en) 2014-09-25
CN104971056A (zh) 2015-10-14

Similar Documents

Publication Publication Date Title
BRPI0707334B8 (pt) formulação de cápsula de gelatina mole de um composto 15-ceto-prostaglandina e método para estabilização do um composto 15-cetoprostaglandina
EA200901319A1 (ru) Композиции для назального введения
MY174001A (en) Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof
BR112013004865A2 (pt) lípidos adequados para entrega lipossomal de codificadores de proteínas rna
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
WO2008063910A3 (en) Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
EP4122451A8 (en) Small liposomes for delivery of immunogen-encoding rna
UA105766C2 (uk) Фармацевтична композиція, яка містить сіль стронцію, вітамін d і циклодекстрин
CY1122416T1 (el) Φαρμακα τα οποια περιεχουν κρυσταλλικες τροποποιησεις (1r,2r)-3-(3-δimeθyλamino-1-αιθυλο-2-μεθυλο-προπυλο)-φαινολης
EA201071218A1 (ru) Улучшенные композиции для активных фармацевтических компонентов с плохой проницаемостью
WO2012097429A8 (en) Probiotic soft gel compositions
BR112012021681A2 (pt) rifaximina em pó, processo para preparação da mesma e composições de liberação controladas contendo a referida rifaximina útil para obtenção de um efeito de longa duração.
MY153805A (en) Nicotine containing soft gelatin pastilles
GB2501219A (en) Orally bioavailable peptide drug compositions and methods thereof
UA102254C2 (ru) Жидкий состав для деферипрона с приятным вкусом
EA201290985A1 (ru) Пероральные ветеринарные фармацевтические и нутрицевтические композиции
EP2524687A3 (en) Edible jelly-form composition, jelly-form preparation and method for producing jelly-form preparation
NO20082181L (no) Formuleringer av Fispemifen
EA201270573A1 (ru) Гранулированный в расплаве цинакальцет
WO2005107709A3 (en) Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients
BR122016006880B8 (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
WO2011083402A3 (en) Immediate release compositions of acid labile drugs
WO2012063005A3 (fr) Composition pharmaceutique et forme galenique a base de dronedarone et son procede de preparation
UA109544C2 (uk) Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення
WO2007086541A3 (en) Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: R - TECH UNEO, LTD. (JP) , SUCAMPO AG (CH)

Free format text: TRANSFERIDO PARTE DOS DIREITOS DE: R-TECH UENO, LTD.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/01/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF